Wegovy vs Zepbound: total cost of treatment, year 1 vs year 5

Five years of Zepbound cash-pay runs about $27,000. The same five years on PA-approved insurance runs about $1,500. Wegovy cash-pay through NovoCare lands around $21,000, Zepbound through LillyDirect around $27,000. HSA dollars cut another 22 to 32 percent off whatever you pay. Zepbound delivers more weight loss per dollar at the maximum dose; Wegovy delivers more per dollar at a sub-maximum dose. Here is the math.

What your dollars buy

Per the registration trials:

• Wegovy 2.4 mg semaglutide weekly: 14.9 percent mean body weight loss at 68 weeks (STEP-1, NEJM 2021).
• Zepbound 15 mg tirzepatide weekly: 22.5 percent at 72 weeks (SURMOUNT-1, NEJM 2022).
• Zepbound 10 mg: 21.4 percent.
• Zepbound 5 mg: 16.0 percent, roughly equal to Wegovy 2.4 mg.

The clean comparison is Wegovy 2.4 mg against Zepbound 5 mg: roughly equal outcomes. Higher Zepbound doses produce more loss. Wegovy has one step left above 2.4 mg. The June 2026 label permits 7.2 mg weekly after four weeks at 2.4 mg.

The four pricing rails

• Commercial insurance with PA: $25 to $150 per month copay after prior authorization.
• Manufacturer direct cash-pay: NovoCare Wegovy $199 to $399/mo, LillyDirect Zepbound $299 to $449/mo. Neither bills insurance. If your plan covers the drug, the copay path beats the cash price.
• HSA or FSA: pays any of the above with pre-tax dollars, cutting the effective cost by your marginal tax rate.
• Compounded semaglutide: $99 to $250/mo, through compounding pharmacies (a different drug, see our compounded explainer).

The savings cards sit on top. Novo's Wegovy Savings Card can bring a commercial-insurance copay to as low as $0 for up to 13 months, with a $225/month cap. Lilly's Zepbound Savings Card can drop the copay to $25 for the first month and up to $150 off later fills, with a 12-month cap. Neither card works with Medicare, Medicaid, or Tricare; pairing a manufacturer card with government insurance is an anti-kickback violation. Lilly launched the Zepbound vial in late 2024 below the pen, $349 against $549 for the 2.5 mg starter, and now prices vial and KwikPen the same. The medication is identical, so choose on handling.

Year 1 cash-pay cost

Cash-pay Year 1 runs roughly $3,700 to $5,400 across the branded paths, depending on the dose you stabilize at.

Year 1 with insurance or an HSA

With PA approved, copays at most large commercial plans run $25 to $50 on a preferred brand (Tier 2), $75 to $150 non-preferred (Tier 3), and $150 to $500 on specialty (Tier 4), the same for either drug. Add the savings card and Year 1 lands around $300 to $1,800. An HSA pays qualified expenses with pre-tax dollars, so the discount tracks your marginal rate. On a $4,188 Wegovy year:

Add state tax and FICA where they apply: a 22 percent federal plus 5 percent state saver drops a $4,188 bill to about $3,057. HSA dollars do not stack with savings cards, but they can pay an insurance copay for the same discount. The IRS treats compounded and FDA-approved medication the same for HSA eligibility, and the 2026 family HSA contribution max is $8,550.

Year 5: the long-run math

Most patients stay on the drug, because stopping at goal weight produces regain. STEP-5, SURMOUNT-4, and SELECT all show continuers hold the loss and quitters regain. So the multi-year bill is what actually matters.

The five-year spread runs from about $1,500 (insurance Tier 2 plus savings card) to about $27,000 (Zepbound cash all-in). The same molecule and the same outcome, at an 18x price difference.

The Zepbound efficiency premium

Cost per percent of weight loss, cash-pay:

• Wegovy 2.4 mg: $4,188/year for 14.9 percent = $281 per percent.
• Zepbound 5 mg: $4,788/year for 16.0 percent = $299 per percent.
• Zepbound 15 mg: $5,388/year for 22.5 percent = $239 per percent.

Zepbound at 15 mg is the most cost-efficient FDA-approved cash-pay path per percent lost. Lilly holds its self-pay price flat at $449 from 7.5 mg upward, so escalating the dose costs nothing extra while the expected loss keeps rising. A patient who stabilizes at 5 mg still pays less per month than one at 15 mg, $399 against $449, and that $50 gap buys far more weight loss than it costs.

What the tables leave out

• Prescriber visits. $40 to $200/mo at most cash-pay telehealth programs, often already in the listed price. A PCP path adds $0 to $50 per visit.
• Lab work. Baseline metabolic panel, A1c, and lipids run $100 to $300 cash, $0 to $50 insured. Repeat annually.
• Side-effect management. Anti-nausea ondansetron is $5 to $20/mo if needed.

Budget another $500 to $1,500 a year for these across most paths.

Medicare and the compounded route

Medicare does not cover Wegovy or Zepbound for weight loss. The one exception is Wegovy for cardiovascular risk reduction in established CVD patients, covered under Part D since 2024 after the SELECT trial. For a pure weight-loss indication on Medicare, cash-pay through NovoCare or LillyDirect is the only path, at $21,000 to $27,000 over five years. Paying cash with no insurance, compounded semaglutide runs $6,000 to $15,000 over five years for a comparable semaglutide outcome, though tirzepatide is harder to source compounded in 2026. See our compounded vs branded explainer.

One more variable is coming. The first generic injectable semaglutide is expected in late 2026 to early 2027. Multi-source generic pricing typically lands 70 to 90 percent below branded, so a $349/month Wegovy bill could become $99 to $149. Any Year-5 math starting in 2026 should assume meaningful drops in years 3 to 5.

Line up every program on price and terms on our comparison chart, or read the full review on the Ro Body page.